129.20Open129.20Pre Close0 Volume1 Open Interest135.00Strike Price0.00Turnover0.00%IV4.28%PremiumDec 20, 2024Expiry Date118.35Intrinsic Value100Multiplier24DDays to Expiry10.85Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.14Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet